BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 12855653)

  • 1. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms.
    Nakamori M; Fu X; Meng F; Jin A; Tao L; Bast RC; Zhang X
    Clin Cancer Res; 2003 Jul; 9(7):2727-33. PubMed ID: 12855653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer.
    Nakamori M; Fu X; Pettaway CA; Zhang X
    Prostate; 2004 Jun; 60(1):53-60. PubMed ID: 15129429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
    Fu X; Tao L; Zhang X
    Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma.
    Fu X; Nakamori M; Tao L; Amato R; Zhang X
    Int J Oncol; 2007 Jun; 30(6):1561-7. PubMed ID: 17487379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.
    Fu X; Zhang X
    Cancer Res; 2002 Apr; 62(8):2306-12. PubMed ID: 11956088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The construction of recombinant type I herpes simplex virus carrying GALV.fus gene and its antitumor effect in nude mice].
    Zhu M; Yang JR; Jiang YQ; Chen SF; Fu XP; Tian ZD
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Mar; 42(2):152-6. PubMed ID: 21500543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
    Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
    Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer.
    Coukos G; Makrigiannakis A; Kang EH; Caparelli D; Benjamin I; Kaiser LR; Rubin SC; Albelda SM; Molnar-Kimber KL
    Clin Cancer Res; 1999 Jun; 5(6):1523-37. PubMed ID: 10389942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice.
    Chung YS; Miyatake S; Miyamoto A; Miyamoto Y; Dohi T; Tanigawa N
    Int J Oncol; 2006 Apr; 28(4):793-8. PubMed ID: 16525626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.
    Li H; Dutuor A; Fu X; Zhang X
    J Gene Med; 2007 Mar; 9(3):161-9. PubMed ID: 17266169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
    Fukuhara H; Ino Y; Kuroda T; Martuza RL; Todo T
    Cancer Res; 2005 Dec; 65(23):10663-8. PubMed ID: 16322208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
    Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
    Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma.
    Li H; Dutuor A; Tao L; Fu X; Zhang X
    Clin Cancer Res; 2007 Jan; 13(1):316-22. PubMed ID: 17200370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic herpes simplex virus vectors for the treatment of human breast cancer.
    Liu RB; Rabkin SD
    Chin Med J (Engl); 2005 Feb; 118(4):307-12. PubMed ID: 15740669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus.
    Fu X; Tao L; Cai R; Prigge J; Zhang X
    Mol Ther; 2006 May; 13(5):882-90. PubMed ID: 16569513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic herpes simplex virus vectors for cancer virotherapy.
    Varghese S; Rabkin SD
    Cancer Gene Ther; 2002 Dec; 9(12):967-78. PubMed ID: 12522436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.
    Simpson GR; Han Z; Liu B; Wang Y; Campbell G; Coffin RS
    Cancer Res; 2006 May; 66(9):4835-42. PubMed ID: 16651439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
    Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A
    Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
    Han ZQ; Assenberg M; Liu BL; Wang YB; Simpson G; Thomas S; Coffin RS
    J Gene Med; 2007 Feb; 9(2):99-106. PubMed ID: 17256802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.